Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Investor Presentation (August 2025)
18 slides from Trendlines's investor presentation, August 2025
Slide 1: Succeeding Together
Succeeding Together Transforming futures in medtech & agrifood August 2025
Slide 2: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Who we are
Who we are We have built & continue to invest in our broad medtech and agrifood portfolio. Our goal is to achieve significant exits from our portfolio, bringing value to our shareholders. Trendlines is an Israel-headquartered company that trades in Singapore on the SGX (42T) and in the USA on the OT
Slide 4: Leadership
Leadership Haim Brosh Barak Singer Nitza Kardish PhD Executive Director & Executive VP & Head of CEO, Agrifood Steve Rhodes CEO Healthcare Fund; Vice Chair, Founder & Chair Emeritus AFIC 25 years’ managerial Trendlines’ Founder; over and financial Extensive investment Vast experience in 40 years’ ex
Slide 5: Board of Directors
Board of Directors Nehama Ronen Sin Boon Ann Haim Brosh Chair Independent Director Executive Director, CEO and Interim CFO 25 years’ experience in public companies. 30 years’ experience 25 years’ managerial She was Director working in the legal and financial General of Israel’s industry and serving
Slide 6: A taste of our portfolio companies
A taste of our portfolio 40 companies * portfolio 12 28 agrifood medtech * including the 6 consolidated portfolio companies in Singapore 6
Slide 7: Portfolio cluster values
Portfolio cluster values Non-IFRS* Value of Trendlines’ Fair Value of Trendlines’ Cluster Share (US$'000) Share (additional information) (US$'000) 30.06.2025 Aquaculture & Animal Health US$ 1,247 US$ 2,261 Crop Protection US$ 5,673 US$ 11,658 Future Food & Ingredients US$ 11,902 US$ 19,376 Digitizat
Slide 8: The natural food color revolution
The natural food color revolution A broad-spectrum of healthy plant-based colors produced via Founded 2018; fermentation technology, using baker’s yeast as a biofactory. Yokne’am Illit, IL Phytolon’s high-quality and cost-effective pigments offer value Co-Founders: for consumers, the environment and
Slide 9: 4 more agrifood frontrunners
4 more agrifood frontrunners 12 agrifood portfolio companies Phage-based solutions for crop Cultivating high quality and high Nanobody-based biological insect Oral delivery platform for the disease control that target bacteria value cocoa ingredients using cell control to uniquely target the and are
Slide 10: Cryotherapy treatment for urological tissue
Cryotherapy treatment for urological tissue A new ablative approach for the treatment of urological tissue with cryotherapy. Founded 2015 Achievements CEO Eyal Kochavi • Closed US$16.5 million investment round including IP Submitted national strategic partner participation phase and PCT • Ongoing cl
Slide 11: 4 more leading medtech companies
4 more leading medtech companies 28 medtech portfolio companies Minimally invasive, nonsurgical, Endoscopic ultrasound fine needle Next-generation aspiration catheter A small, game-changing incision-free and mesh-free repair biopsy system for improve, precise for treating ischemic stroke. device to
Slide 12: H1 2025 financials
H1 2025 financials 12
Slide 13: Balance sheet
Balance sheet Assets (US$’000) Liabilities & Equity (US$’000) Current assets 30 June 2025 31 Dec 2024 Current liabilities 30 June 2025 31 Dec 2024 Cash and cash equivalents 2,681 4,973 Lease liability 265 304 Short-term bank deposits 206 1,014 Short-term loan 1,807 423 Accounts and other Trade and o
Slide 14: Profit and Loss Statements
Profit and Loss Statements (US$’000) Income 30 June 2025 30 June 2024 Loss from change in fair value of investments in portfolio companies (392) 4,494 Income from services to portfolio companies 307 836 Income from contracted R&D services 84 40 Financial income 243 834 Other income 398 193 Total inc
Slide 15: H1 2025: Key Points
H1 2025: Key Points • More portfolio companies increased in value than decreased = overall increase in portfolio value • Significant operating costs reduction, excluding TMS & misappropriated funds • Sharp & consistent portfolio analysis • Appointment of Chief Financial Officer • Announcement of Rig
Slide 16: 2025 selected portfolio news
2025 selected portfolio news For full details, see our news page 16
Slide 17: THANK YOU
THANK YOU +972.72.260.7000 | www.trendlines.com
Slide 18: Notes and Disclaimer
Notes and Disclaimer The non-IFRS fair value information does not represent any forecast or future performance but serves as an extra aid in evaluating our portfolio companies and investment approaches. The additional information (Non-IFRS value) which, as stated, differs from the IFRS fair value at
The Trendlines Group — Investor Presentation (August 2025) on 6ix